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Fulvio Santacatterina1,2,3, María Sánchez‑Aragó1,2,3, Marc Catalán‑García2,4, Glòria Garrabou2,4, 
Cristina Nuñez de Arenas1,2,3, Josep M. Grau2,4, Francesc Cardellach2,4 and José M. Cuezva1,2,3*
Abstract 
Background: Metabolic alterations play a role in the development of inflammatory myopathies (IMs). Herein, we 
have investigated through a multiplex assay whether proteins of energy metabolism could provide biomarkers of IMs.
Methods: A cohort of thirty‑two muscle biopsies and forty plasma samples comprising polymyositis (PM), dermato‑
myositis (DM) and sporadic inclusion body myositis (sIBM) and control donors was interrogated with monoclonal 
antibodies against proteins of energy metabolism using reverse phase protein microarrays (RPPA).
Results: When compared to controls the expression of the proteins is not significantly affected in the muscle of PM 
patients. However, the expression of β‑actin is significantly increased in DM and sIBM in consistence with muscle 
and fiber regeneration. Concurrently, the expression of some proteins involved in glucose metabolism displayed a 
significant reduction in muscle of sIBM suggesting a repression of glycolytic metabolism in these patients. In contrasts 
to these findings, the expression of the glycolytic pyruvate kinase isoform M2 (PKM2) and of the mitochondrial ATPase 
Inhibitor Factor 1 (IF1) and Hsp60 were significantly augmented in DM when compared to other IMs in accordance 
with a metabolic shift prone to cancer development. PKM2 alone or in combination with other biomarkers allowed 
the discrimination of control and IMs with very high (>95%) sensitivity and specificity. Unfortunately, plasma levels of 
PKM2 were not significantly altered in DM patients to recommend its use as a non‑invasive biomarker of the disease.
Conclusions: Expression of proteins of energy metabolism in muscle enabled discrimination of patients with IMs. 
RPPA identified the glycolysis promoting PKM2 and IF1 proteins as specific biomarkers of dermatomyositis, providing 
a biochemical link of this IM with oncogenesis.
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Background
Inflammatory myopathies (IMs) is a group of hetero-
geneous diseases characterized by muscle weakness 
and inflammatory infiltrates within the skeletal muscle. 
Despite presenting unknown etiology, inflammatory and 
bioenergetic disturbances have been argued in most of 
cases. Due to their similar clinical presentation, polymy-
ositis (PM), dermatomyositis (DM) and sporadic inclu-
sion-body myositis (sIBM) are the three major groups 
ascribed to IMs [1]. A fourth and fifth subtypes termed 
necrotizing auto-immune myositis and overlap myositis 
are also being recognized within the group of IMs [2]. 
IMs are considered rare diseases due to their low inci-
dence, about of 2.1 to 7.7 new cases per every million 
inhabitants/year. sIBM is the most common acquired 
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myopathy in patients above 50  years, with some geo-
graphical differences [3–5]. There are few biomarkers 
that could help the diagnosis and management of patients 
affected by IMs, in particular myositis-associated or spe-
cific antibodies. The elevated serum activity of creatine 
kinase, lactate dehydrogenase and aldolase are currently 
used as activity indicators of all subtypes of IMs [2].
Reverse phase protein microarrays (RPPA) is a high-
throughput quantitative technique adequate for multi-
plexed analysis of protein expression in minute amounts 
of sample in a large variety of biological specimens [6, 7]. 
Over the last decade, RPPA technique has provided a pre-
cious tool in the discovery of biomarkers of disease which 
might become indispensable in the progress of diagnos-
tic, prognostic and therapeutic fields. The Achilles heel 
for the development of a reliable RPPA platform, is the 
availability of high-affinity and specific antibodies against 
the proteins investigated [8, 9]. Herein, we have studied 
the putative relevance of proteins of energy metabolism 
as diagnostic biomarkers in IMs using RPPA. To this aim, 
we have studied the expression of enzymes of glucose 
metabolism and of oxidative phosphorylation in a cohort 
of thirty-two muscle biopsies including samples from 
control and PM, DM and sIBM affected patients using 
validated monoclonal antibodies. The final purpose of the 
study is to translate the “signature” of energy metabolism 
to bed-side application of patients affected with IMs.
Methods
Patients and protein extraction
A cohort of thirty-two muscle biopsies from a deltoid or 
quadriceps muscle was collected. The muscle biopsy was 
immediately frozen in liquid N2 cooled isopenthane and 
stored at −80  °C until histological sectioning for diag-
nostic procedures. In brief, 8–10 microns cryotome sec-
tions were obtained and processed for histopathological 
and molecular and clinical diagnosis by the same expert 
pathologist (JMG). The final diagnosis of the cohort was: 
4 PM, 13 DM, 9 sIBM and 6 healthy controls. In all the 
cases the biopsies were obtained for diagnostic pur-
poses, and all the patients signed an informed consent 
before the procedure for further used of their samples 
in research. In addition, forty plasma samples of control 
donors (n =  10) and patients affected with IMs includ-
ing PM (n  =  5), DM (n  =  9) and sIBM (n  =  16) were 
also collected. The samples were obtained from lefto-
ver biological material from diagnostic procedures with 
informed consent following the Declaration of Helsinki 
and coded for anonymity to protect patient confidential-
ity. The Institutional Review Board approved the project. 
For protein extraction from muscle biopsies, the samples 
were homogenized in T-PER Tissue Protein Extraction 
Reagent (ThermoScientific, Inc.) containing protease 
inhibitors (Roche) in a 1:5 (w/v) ratio, and further freeze–
thawed three times in liquid nitrogen [10]. The protein 
concentration was determined with the Bradford reagent 
(Bio-Rad, Inc) using BSA as standard.
Protein electrophoresis and western blotting
Protein samples from muscle biopsies were fractionated 
on SDS–9% PAGE and blotted with anti-β-F1-ATPase 
(1:1000), anti-Hsp60 (1:1000), anti-GAPDH (1:1000) and 
anti-PKM2 (1:1000) from [11], anti-IF1 (1:500) from [12], 
anti-LDH-A (1:1000), anti-GPD1 (1:1000) from [13], anti-
PYGM (Abcam, ab88078; 1:1000), anti-PKM1 (Abcam, 
ab6191-5; 1:1000), anti phospho-PKM2 (Tyr105) (Cell 
Signaling, #3827; 1:1000), anti-PDHE1α (Invitrogene, 
459400; 1:500), anti-phospho-PDHE1α (Ser293) (Abcam, 
ab92696; 1:1000), anti-PDK1 (Abcam, ab207450; 1:1000) 
and anti-β-actin (Sigma-Aldrich, A1978; 1:1000). Perox-
idase-conjugated anti-mouse IgGs (Nordic Immunology; 
1:3000) were used as secondary antibodies. The blots 
were revealed using the ECL® reagent (Amersham Phar-
macia Biotech). The intensity of the bands was quantified 
using a Kodak DC120 digital camera and the Kodak 1D 
Analysis Software.
Printing and processing of reverse phase protein 
microarrays
Samples from muscle biopsies were diluted in PBS to a 
final protein concentration of 0.75  μg/μl before print-
ing. Serially diluted protein extracts (0–1 μg/μl) derived 
from HCT116 colocarcinoma cells were also prepared to 
assess printing quality and the linear response of protein 
recognition by the antibodies used. A standard curve of 
BSA (0–1 μg/μl) and mouse IgGs (0–1 ng/ml) were also 
prepared for printing as internal negative and positive 
controls, respectively. Plasma samples were diluted 1:20 
(v/v) in PBS before printing. A Standard curve (0–1 ng/
ml) of the PKM2 recombinant protein (r-PKM2) was 
printed to correlate the mean fluorescent intensity of the 
samples to the quantity of the protein. Approximately, 
1 nl volume of each sample was spotted in triplicate onto 
nitrocellulose-coated glass slides (FAST Slides, Sche-
leicher & Schuell BioScience, Inc.) using a BioOdyssey 
Calligrapher MiniArrayer printer (Bio-Rad Laboratories, 
Inc.) equipped with a solid pin (MCP310S) at constant 
humidity (RH 45%) and temperature (16 °C).
After printing, arrays were allowed to dry and further 
blocked in PBS-T containing 5% skimmed milk. An addi-
tional blocking step with goat anti-human whole serum 
IgGs (Sigma-Aldrich, I1011; 1:100) was necessary to pre-
vent the cross reaction of the secondary antibody with 
plasma IgGs. After, the arrays were incubated overnight 
at 4  °C with the indicated concentrations of the follow-
ing primary monoclonal antibodies: anti-β-F1-ATPase 
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(1:150), anti-Hsp60 (1:150), anti-GAPDH (1:250) and 
anti-PKM2 (1:150), anti-IF1 (1:150), anti-LDH-A (1:200), 
anti-GPD1 (1:1000), anti-PYGM (1:200) and anti-β-actin 
(1:1000). After incubation, the arrays were washed with 
PBS-T and further incubated with a donkey anti-mouse 
secondary antibody conjugated with alexa-555 (Invit-
rogen, Madrid, Spain) or, in the case of arrays of plasma 
samples, incubated with goat anti-mouse highly cross-
adsorbed antibody conjugated with CF™647 (Sigma-
Aldrich, SAB4600183; 1:500). To evaluate the unspecific 
binding of the secondary antibody to non-masked human 
IgGs in plasma samples, a pad was incubated directly 
with the secondary antibody as negative control of the 
RPPA analysis. Spotted samples in one of the pads were 
fixed with XFCF buffer (10% acetic acid, 30% ethanol) 
for 1  h, stained with 0.0001% Fast Green FCF (Sigma-
Aldrich, F7252) in XFCF for 5 min and washed 5 times 
with XFCF in order to quantify the total protein amount 
of each spot. Microarrays were scanned using a Typhoon 
9410 scanner (GE Healthcare, Inc.). The mean fluores-
cent intensity of the spots was quantified using GenePix® 
Pro 7 software system and converted into arbitrary units 
of expressed protein/ng of protein in the sample using the 
expression obtained in the standard curve of the HCT116 
cell line and normalized to the protein amount in the 
sample obtained from the FCF stained pad. Representa-
tive technical variances of the PKM2 arrays, calculated by 
the squared coefficient of variation (SCV  =   σ*100/|x|), 
were 2.7   ±   0.4 for muscle samples and 3.2  ±  0.4 for 
plasma samples.
Indirect ELISA
Plasma samples (50  μl) from IBM (n =  8), DM (n =  9) 
patients and a control group (n  =  8) were absorbed in 
F96 IMMUNO PLATE (NUNC, 442404) for 1 h at 37 °C. 
A standard curve (0–4 μg/ml) of the recombinant PKM2 
(r-PKM2) [11] was also adsorbed. After blocking and 
extensive washing, 50 μl of a solution containing mouse 
anti-PKM2 (1:150) were added to each well and incu-
bated at 37  °C for 1  h. Wells were washed with PBS-T, 
and after 50  μl of horseradish peroxidase-labeled goat 
anti-mouse IgG (1:1000) (Bio-Rad Laboratories, 172-
1011) were added. Color development was achieved by 
addition of 200  μl of the peroxidase substrate solution 
(Bio-Rad Laboratories, Inc., 172-1064). Reaction was 
stopped by addition of 100 μl/well of 2% oxalic acid. The 
absorbance at 415  nm was measured with a FLUOstar 
OMEGA Microplate Reader (BMG LABTECH).
Immunofluorescence microscopy
Formalin fixed cryostat tissue sections were used to 
analyze the subcellular localization of PKM2 in muscle 
of control and DM patients. The primary anti-PKM2 
antibody was used at a 1:200 dilution. Slides were incu-
bated for 2  h in the dark with anti-mouse IgGs conju-
gated to Alexa Fluor® 488. Nuclei were counter stained 
with DAPI (diamidino-2-fenilindol) reagent. Cellular 
fluorescence was analyzed by confocal microscopy in a 
Nikon A1R + microscope.
Statistical analysis
Distribution of molecular markers was studied by using a 
two-tailed Student’s t test. Analysis of variance (ANOVA) 
with post hoc Dunnett’s test was used for multiple com-
parisons to the control. Inter-individual variation of 
the expression of protein levels in muscle biopsies were 
shown in box plots graphs, using the PASW statistics 18 
software package. For the expression profiles of meta-
bolic markers data were reformatted by calculating the 
log2 of the expression level in each sample relative to the 
mean expression level in normal samples. We used the 
Cluster Program from “Expression Profiler Clustering 
home page” at http://ep.ebi.ac.uk/EP/EPCLUST by the 
Average Linkage (Weighted Pair Group Method Aver-
age WPGMA) clustering based on the Euclidean distance 
function as proximity measure. Nonparametric receiver 
operating characteristic (ROC) curves were generated to 
plot the sensitivity of the assay against the false-positive 
rate (1-specificity). The area under the curve (AUC) was 
calculated to illustrate the sensitivity and specificity of 
the biomarkers. The results shown are mean ± S.E.M. A 
p < 0.05 was considered statistically significant.
Results
To explore the potential applicability of a signature of 
metabolism in the diagnosis of IMs we selected for study 
representative proteins from glycogenolysis (Glyco-
gen phosphorylase, PYGM), glycolysis (glyceraldehyde-
3-phosphate dehydrogenase, GAPDH, pyruvate kinase 
M2, PKM2 and lactate dehydrogenase A, LDHA), oxida-
tive phosphorylation (β-subunit of the H+-ATP synthase, 
β-F1-ATPase and ATPase Inhibitory Factor 1, IF1), and 
electron shuttling of glycolytic NADH to mitochondria 
(glycerol-phosphate dehydrogenase 1, GPD1). In addi-
tion, β-actin and heat shock protein 60 kDa (Hsp60) were 
also studied as structural markers of the cell and mito-
chondria, respectively. The major limitation of quan-
titative RPPA is the availability of specific monoclonal 
antibodies (mAbs) against the proteins being studied. 
Figure 1 shows that the mAbs used in this study only rec-
ognized a single protein band at the expected molecular 
weight in human muscle extracts validating their utiliza-
tion in RPPA techniques [11–13].
A representative protein microarray illustrating the 
printing protocol of human muscle biopsies developed 
with antibodies against the glycolytic PKM2 is shown in 
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Fig.  2a. Microarrays developed with the other antibod-
ies are shown below (Fig. 2a). Protein extracts from mus-
cle biopsies of control (green boxed in Fig. 2a), PM, DM 
and IBM (yellow, red and blue boxed in Fig. 2a, respec-
tively) were prepared and spotted onto RPPA in trip-
licate from left to right (Fig.  2a). Increasing amounts of 
BSA and murine IgGs (black and brown boxed in Fig. 2a, 
respectively) were spotted in the array as control of the 
background of the assay and positive control of antibody 
recognition, respectively. Increasing protein amounts of 
cellular extracts derived from HCT116 cells were also 
spotted (magenta boxed in Fig. 2a). The HCT116 extracts 
revealed a linear increase in fluorescent intensity as the 
amount of protein increases (Fig. 2b), providing the linear 
plot of the assay (Fig. 2b, see also Additional file 1: Figure 
S1 for the rest of the mAbs tested). The arrays illustrate 
the specific recognition of the corresponding antigen in 
minute amounts of protein of HCT116 extracts as well 
as in the biopsies (Fig.  2a). As expected BSA did not 
show any fluorescent signal, confirming the absence of 
non-specific binding of the primary and secondary anti-
bodies onto the spotted proteins (Fig.  2a). In contrast, 
a linear increase in signal was observed in murine IgGs 
(Fig. 2a), confirming that the secondary antibody works 
properly. The quantification of the expression of each 
marker in control (n = 6) and patient (n = 26) biopsies 
was calculated by interpolating the fluorescent inten-
sity signal obtained in the sample in the standard curve 
of HCT116 cells (Fig.  2b and Additional file  1: Figure 
S1). The box plots in Fig. 3 display the results of protein 
expression in PM, DM and sIBM when compared to con-
trols revealing the inter-individual variation within each 
group.
Interestingly, only DM and sIBM patients showed sig-
nificant alterations of the expression level of the studied 
markers when compared to controls (Fig. 3). Muscle biop-
sies from patients affected with DM showed an increase 
in the expression of Hsp60 and β-actin concurrent with 
a similar increase in the expression of PKM2 and the 
mitochondrial ATPase inhibitor factor IF1 (Fig. 3). These 
changes occurred in the absence of relevant changes for 
the expression of other markers and with a significant 
reduction in PYGM expression (Fig. 3). In contrast, biop-
sies from sIBM patients showed a significant reduction 
in the expression of the cytoplasmic GAPDH, LDH-A, 
PYGM, GPD1 and mitochondrial Hsp60 (Fig. 3). Concur-
rently, a significant increase in β-actin and IF1 expres-
sion (Fig.  3) was observed in sIBM. Overall, and from 
the point of view of a potential biomarker to distinguish 
between DM from normal biopsies and the rest of the 
other IMs stands the sharp increase in PKM2, IF1 and 
Hsp60 expression (Fig. 3). In fact, PKM2 alone achieved a 
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Fig. 1 Validation of the antibodies used in RPPA. Tissue extracts (40 µg) derived from human muscle (M) were fractionated on SDS‑PAGE gels, 
blotted against the indicated antibodies and processed for western blotting. Only antibodies that recognize a single protein band of the expected 
molecular mass were used in the study. The migration of molecular mass markers is indicated to the left
(See figure on next page.) 
Fig. 2 Printing of RPPA. a The scheme of printing of RPPA processed for PKM2 is shown magnified for details. One nl samples were spotted in tripli‑
cate. Black boxed negative controls of BSA; Magenta boxed standard curves of HCT116 cells; Brown boxed positive controls of murine IgGs; Green boxed 
samples from control donors; Yellow boxed PM samples; Red boxed DM samples; Blue boxed sIBM samples. Below are shown representative RPPAs 
processed with other antibodies. b The plot illustrates the linear correlation that exists between the fluorescence intensity (arbitrary units, a.u.) and 
the amount of PKM2 in HCT116 cell lysates. Protein content in the biopsies was calculated according to the fluorescence intensity obtained in the 
standard curve of HCT116 cells. For other details see Additional file 1: Figure S1
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sensitivity of 96.1% and specificity of 100% (AUC of 0.988) 
(Fig. 4). Details of the sensitivity (ROC) for IF1 and Hsp60 
are provided in Additional file  2: Table S1). In the same 
line, the down-regulation of glycolytic markers distin-
guishes sIBM from control biopsies and other IMs (Fig. 3; 
and see Additional file 2: Table S1).
Representative western blot analysis of the three gly-
colytic markers investigated in RPPAs (Additional file 3: 
Figure S2) confirmed the higher expression of PKM2 in 
DM samples and the downregulation of both GAPDH 
and LDH-A in sIBM biopsies when compared to control 
or PM samples. Interestingly, PKM2 expression in DM 
was as high as in the HCT116 carcinoma cell line (Addi-
tional file 3: Figure S2). A helpful biomarker that informs 
of the relative activity of energy provision pathways 
during development, differentiation and in cancer is the 
bioenergetic signature [10, 14, 15]. The bioenergetic sig-
nature is calculated by the ratio between the catalytic 
subunit of the H+-ATP synthase (β-F1-ATPase) relative 
to the expression of a glycolytic enzyme [14]. Remark-
ably, the β-F1-ATPase/PKM2 ratio was significantly 
diminished in DM providing an excellent bioenergetic 
marker in order to discriminate this disorder from con-
trols or any other IM (Fig. 5a; Table 1). Likewise, unsu-
pervised hierarchical clustering of the biopsies using the 
expression of 1, 2 or 3 proteins for aggregation further 
illustrated the potential of metabolic biomarkers to dis-
criminate normal biopsies from DM (Fig.  5b; Table  1) 
and from sIBM (Fig. 5c; Table 1) with very high sensitiv-
ity and specificity (Fig. 5; Table 1).
* *
*
** *
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P< 0.05
P< 0.05
P< 0.05 P< 0.05
* *
P< 0.001
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P< 0.05
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Fig. 3 Expression of proteins of energy metabolism in IMs. The Y axis indicates the values of intensity (a.u) calculated by interpolation in the linear 
plot of HCT116 cells. The X axis represents patient samples from PM, DM and sIBM and the control (CTR) group. Box plots represent the lowest, 
lower quartile, median, upper quartile and highest observations of each marker in the different groups of pathologies. ○ and *, outlier and extreme 
values, respectively. The boxed * and ** in the X‑axis indicates a p < 0.05 and p < 0.001 when compared to controls by Student’s t test, respectively
Page 7 of 13Santacatterina et al. J Transl Med  (2017) 15:29 
To further explore the potential bed-side translation 
of PKM2 as a non-invasive biomarker of DM we inves-
tigated whether the inflammation and tissue remode-
ling that accompanies the disease could be reflected on 
the plasma levels of PKM2. To this aim we studied the 
expression of PKM2 in plasma samples of control and IM 
patients by ELISA and by a modified RPPA technique. 
Unfortunately, the results obtained revealed that IMs do 
not modify plasma PKM2 levels to a significant extent 
when compared to controls (Additional file 4: Figure S3).
In an effort to provide some basic information regard-
ing the expression and regulation of PKM2 in muscle of 
DM patients we also studied the expression of the PKM1 
isoform. We found that expression of PKM1 is not altered 
in the muscle of DM patients when compared to con-
trol samples (Fig. 6a). Due to the very large induction of 
PKM2 observed in muscle of DM patients (Figs. 3, 6a) the 
results support that rather than a switch in the expres-
sion of PK isoforms DM triggers the specific induction of 
PKM2. Likewise, analysis of the phosphorylation status 
of PKM2 in muscle of control and DM patients using the 
105Tyr PKM2 antibody revealed, despite the large intra-
group variability noted in the phosphorylation of the pro-
tein (Fig. 6a), no significant differences between the two 
groups of samples (Fig.  6a). This finding suggests that 
PKM2 induction in the muscle of DM patients accounts 
largely for the active form of the enzyme. Moreover, anal-
ysis of the subcellular localization of PKM2 in cryo-sec-
tions of muscle samples from control and DM patients 
by immunofluorescence microscopy revealed that the 
immunostaining was found in the cytoplasm preferen-
tially clustered towards the sarcolemma and perinuclear 
region of the cells. We found no evidence for PKM2 
translocation into the nucleus of both control and DM 
muscle cells (Fig. 6b).
To evaluate the potential activation of glycolysis in 
the muscle of DM patients as a result of the potential 
limitation of the oxidation of pyruvate in mitochondria 
we studied the expression of pyruvate dehydrogenase 
E1α (PDH) and of its less active phosphorylated form 
(p-PDH) in samples of control and DM patients (Fig. 6c). 
The results obtained support that glucose oxidation 
might be partially restricted in the muscle of DM patients 
when compared to controls because there is a sharp and 
significant increase in the expression of the less active 
p-PDH (Fig.  6c) in the absence of relevant changes 
in total PDH (Fig.  6c). Moreover, these changes were 
further supported by the parallel and significant con-
current increase in the expression of pyruvate dehydro-
genase kinase (PDK1) in muscle samples of DM patients 
(Fig. 6c).
Discussion
Diagnosis of IMs relies on histopathologic and immu-
nopathologic examination of muscle biopsies by an 
experienced laboratory [2, 16]. Specific myositis-related 
autoantibodies may help diagnosis [17, 18]. Although the 
diagnosis of DM usually is not difficult based on clinical 
signs and symptoms, this is not the case with respect to 
PM and sIBM. The diagnosis of PM is often assessed by 
exclusion criteria [1], and in turn, usually more than one 
or two biopsies over time are required before reaching 
the diagnosis of sIBM. RPPA is a widely adopted high-
throughput technique that allows quantitative protein 
profiling of cells or tissues that is especially indicated for 
the identification of biomarkers of diagnosis, prognosis 
and therapeutic response [6, 10, 19, 20]. In fact, RPPA 
have been recently approved for implementation in clini-
cal trials [6]. Herein, we have interrogated a cohort of 
muscle biopsies from inflammatory myopathic patients 
using RPPA and nine validated mAbs against key proteins 
of energy metabolism to uncover new biomarkers that 
could help differential diagnosis of IMs. We report that 
the metabolic biomarkers studied are unable to distin-
guish control from PM biopsies suggesting the lack of a 
specific molecular fingerprint of the disease in agreement 
with its ambiguous clinical profile. In contrast, both DM 
and sIBM reveal significant differences in the expression 
of proteins of energy metabolism when compared to con-
trols according to a well-defined clinical profile. Although 
age, type of muscle fibers and extent of cellular damage in 
the biopsies are likely to affect protein expression, the low 
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Fig. 4 Diagnostic performance of PKM2 in inflammatory myopathies. 
ROC was plotted to describe PKM2 performance characteristics in a 
32 subject cohort. 95% IC 0.961–1.000; P = 0.000 AUC, area under the 
curve
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dispersion of the values obtained for each marker sug-
gests that these are not main factors contributing to the 
differences reported.
Consistent with previous reports [16] we observed 
an increased expression in β-actin in both DM and 
sIBM. β-actin overexpression in IMs is the likely con-
sequence of muscle fiber regeneration, a criteria for 
the classification of IMs [16] also supported by their 
association with connective tissue disorders [21, 22]. 
Contrary to the increased expression of β-actin, sIBM 
biopsies revealed a diminished expression of the glyco-
lytic markers GAPDH and LDHA when compared to 
controls. Consistently, the expression of GPD1, which 
forms part of the mitochondrial shuttle of the glycolytic 
Fig. 5 Hierarchical clustering analyses of the biopsies using the expression level of enzymes of energy metabolism. Rows indicate type of sample; 
columns, proteins and derived ratios. Protein expression scores are shown normalized to the mean relative expression level in normal samples in 
(a–c), according to a color scale (below panels): red, high; black, normal; green, low expression. The dendogram (to the right of the matrix) represents 
overall similarities in expression profiles. The maximum and minimum values of the markers for each cluster are shown. a Clustering of control (CTR), 
DM, PM and sIBM biopsies using βF1‑ATPase/PKM2 ratio as biomarker. b Clustering of CTR and DM biopsies using PKM2 expression as biomarker. c 
Clustering of CTR and sIBM biopsies using βF1‑ATPase/LDHA ratio and β‑actin as biomarkers. d Scheme showing the contribution of four biomark‑
ers to discriminate CTR, DM and sIBM biopsies attending to high (red) or low (green) expression levels. For additional details see Table 1
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generated NADH, was also diminished in sIBM. More-
over, the expression of PYGM, which is upstream of 
glycolysis, was also diminished in sIBM biopsies. These 
findings suggest that muscle fibers of sIBM experience 
a partial repression of glycolytic metabolism when 
compared to controls in agreement with recent prot-
eomic findings in this regard [23].
In contrast to the findings in muscle of sIBM, the 
biopsies of DM patients showed an enhanced expres-
sion of the mitochondrial protein Hsp60 and IF1 and a 
very large increase in the glycolytic PKM2. The βF1-
ATPase/LDHA ratio, which has been recently described 
as a potential biomarker of neuromuscular diseases 
[13], failed in the discrimination of IMs except for sIBM 
patients, which showed an increase of the ratio. However, 
the βF1-ATPase/PKM2 ratio offered a reliable indicator 
to discriminate DM from any other IM or from control 
biopsies. In fact, the power of PKM2 as a biomarker in 
IMs is well demonstrated by the high specificity and 
sensitivity in the stratification of patients affected with 
DM when compared to controls or any other group of 
patients affected with IMs. Overall, we support that the 
increased expression of PKM2 in DM confers to this pro-
tein a great value as biomarker for this particular type of 
IM, a finding that might benefit some patients by spar-
ing an additional muscle biopsy [16]. Unfortunately, we 
found that PKM2 levels in plasma of DM patients do not 
provide a non-invasive biomarker of the disease.
It is generally agreed that cancer is more frequently 
associated with DM than with PM [2] and a clear increase 
of cancer related mortality has been reported in DM 
patients when compared to PM patients [1, 24–26]. A 
distinctive feature of cancer cells is the enhanced aero-
bic glycolysis [14, 27]. Pyruvate kinase (PK) is the enzyme 
that catalyzes the final step in glycolysis, converting phos-
phoenolpyruvate (PEP) to pyruvate [28]. Four different 
isoforms of pyruvate kinase exist: type-R and type-L are 
generated by alternative splicing of the PKLR gene and are 
expressed in erythrocytes and in liver, respectively [29]. 
PKM1 is the isoform expressed in adult skeletal muscle 
while PKM2, which results from alternative splicing of the 
PKM gene is expressed exclusively in embryonic and pro-
liferating tissues. Notably, PKM2 is allosterically regulated 
due to its possibility to switch from a dimeric low-active 
form to a tetrameric very high active form [30–32]. In 
addition, phosphorylation of S37 and Y105 in PKM2 pre-
vents the binding of the PKM2 cofactor fructose-1,6-bi-
sphosphate, thus inhibiting the active tetrameric form 
of PKM2 which promotes aerobic glycolysis and tumor 
growth [33] (Fig. 5). Our findings stress the idea that DM 
triggers an increase in the expression of PKM2 rather 
than a switch in the expression of muscle isoforms. Like-
wise, the increased expression of PKM2 in muscle of DM 
patients is in its non-phosphorylated active state. Moreo-
ver, PKM2 also has a “non-metabolic” role in tumorigen-
esis since its translocation into the nucleus regulates gene 
transcription of several pathways involved in metabolic 
reprogramming, cell proliferation and cancer develop-
ment [34–37]. Although we did not observe any nuclear 
localization of PKM2 in muscle of DM patients, we can-
not exclude this possibility (Fig.  7) because its nuclear 
translocation might represent a late event in the pro-
oncogenic development of the disease.
Strikingly, and highly consistent with the increased 
cancer incidence observed in DM patients [1, 24–26], we 
found an elevated expression of IF1 in DM biopsies. In 
fact, IF1 is highly overexpressed in most prevalent human 
carcinomas [12, 38]. Overexpression of IF1 interferes 
with oxidative phosphorylation by inhibiting the H+-ATP 
synthase promoting aerobic glycolysis and signaling, via 
reactive oxygen species (ROS), a pro-oncogenic pheno-
type (Fig. 7) that enhances proliferation, invasion and cell 
survival [12, 39, 40]. More recently, the overexpression 
of IF1 in human hepatocellular carcinomas, bladder and 
gastric cancers and in gliomas has provided a valuable 
biomarker of bad cancer prognosis [41–44]. Mechanis-
tically, the pro-oncogenic features of IF1 over-expres-
sion stem from its effects on favoring proliferation, cell 
death resistance, epithelial mesenchymal transition and 
angiogenesis [39–41, 45]. Altogether, we suggest that the 
increased expression of PKM2 and IF1 could cooperate 
to promote a metabolic phenotype in DM that is prone 
for the onset of oncogenesis (Fig.  7). Consistent with 
this idea, our findings support that pyruvate oxidation 
Table 1 Diagnostic sensitivity of  some biomarkers 
in inflammatory myopathies
The table summarizes the power to discriminate (sensitivity) the myopathies 
by the value of the indicated markers. Sensitivity was calculated accordingly 
to the classification rate of the positive samples following the formula: 
Sensitivity = true positives/(true positives + false positives). Specificity = true 
negatives/(true negatives + false positives)
Diseases Markers Sensitivity 
(%)
Specificity 
(%)
Controls
All β‑actin PKM2 βF1/Hsp60 96 100
DM PKM2 100 100
sIBM β‑actin βF1/LDHA 100 100
DM
All βF1/PKM2 95 100
CTR 100 100
PM 100 100
sIBM 90 100
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in muscle of DM patients might be partially restricted 
when compared to controls by the diminished fraction of 
active pyruvate dehydrogenase present in mitochondria 
(Fig. 6c). We suggest that these findings might stimulate 
the development of future basic investigations and thera-
peutic approaches for the management of DM patients in 
order to prevent their higher cancer incidence.
Conclusions
Our study highlights the usefulness of combining RPPA 
and proteins of energy metabolism as a tool to iden-
tify novel biomarkers in rare myopathic diseases. We 
further illustrate the clinical relevance of PKM2 and 
IF1, two proteins that respectively act on glycolysis 
and oxidative phosphorylation, as novel biomarkers of 
CTR
PKM2
PKM1
p-PKM2Y105
a
1 2
DM
GAPDH
1 2
PDH
p-PDH
PDK1
c
GAPDH
CTR  DM
CTR
1 2
DM
1 2
b
*
** *
CTR CTR
DM DM
CTR  DM CTR  DM
CTR  DM CTR  DM CTR  DM CTR  DM
Fig. 6 Expression and subcellular localization of PKM2 in muscle of DM patients: impact on pyruvate oxidation. a Tissue extracts (20 µg) derived 
from muscle biopsies of control (CTR) and dermatomyositis (DM) donors were fractionated on SDS‑PAGE and blotted against anti‑PKM1, anti‑PKM2, 
anti‑phospho PKM2Y105 and anti‑GAPDH. Representative blots of two samples (1,2) per condition are shown. Histograms show the expression of the 
proteins in arbitrary units (a.u.) ±S.E.M. of five different muscle samples. *p < 0.05 when compared to controls by Student’s t test. b Representative 
confocal images of control (CTR) and dermatomyositis (DM) cryostat muscle sections incubated with anti‑PKM2 (green) and DAPI (blue). Images 
were taken at 20× and 60×. c Same as in a but blotted with anti‑PDH, anti‑phospho PDH, anti‑PDK1 and anti‑GAPDH. Representative blots of two 
samples (1,2) per condition are shown. b Histograms show the expression of the proteins in arbitrary units (a.u.) ±S.E.M. of five different muscle 
samples. *p < 0.05 when compared to controls by Student’s t test
Page 11 of 13Santacatterina et al. J Transl Med  (2017) 15:29 
dermatomyositis and potential metabolic drivers of the 
higher cancer incidence observed in this inflammatory 
myopathy.
Abbreviations
β‑F1‑ATPase: β‑subunit of the H+‑ATP synthase; DM: dermatomyositis; GAPDH: 
glyceraldehyde‑3‑phosphate dehydrogenase; GPD1: glycerol‑3‑phosphate 
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Fig. 7 Metabolic reprograming in dermatomyositis. The scheme highlights the primary flux of energy provision pathways in the muscle of normal 
and DM patients. In normal muscle, most of the glucose taken up by the cell is oxidized in mitochondria to generate a high yield of ATP by oxida‑
tive phosphorylation. Mitochondrial activity also generates a little amount of reactive oxygen species (ROS) in the respiratory chain. In contrast, in 
muscle cells of DM patients glucose is partially oxidized in the cytoplasm to generate metabolic intermediates by the blockage imposed on the gly‑
colytic pathway by the overexpression of the less active PKM2 isoform. Moreover, the overexpression of IF1 in mitochondria also limits cellular ATP 
availability enforcing aerobic glycolysis and enhancing the production of reactive oxygen species (ROS). Diversion of the glycolytic flux by blockade 
of glycolysis and oxidative phosphorylation provides the metabolic intermediates that become precursors for the biosynthesis of the macromol‑
ecules required for cellular proliferation. In addition, PKM2 can translocate into the nucleus and activates the transcription of several genes involved 
in cancer development [34–37]. Likewise, the IF1‑mediated inhibition of the H+‑ATP synthase generates a ROS signal that activates in the nucleus 
programs involved in proliferation, cell death resistance and invasion [38–44]. Thus, the concurrent increase of PKM2 and IF1 expression in the 
muscle of DM patients leads to metabolic rewiring and ROS signaling that are hallmarks of the oncogenic phenotype
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Additional file 1: Figure S1. Linear correlation between the fluores‑
cence intensity and the content of native proteins. HCT116 cell line 
extracts (0–1 μg/μl) were spotted in the arrays (see Fig. 2a). Significant 
linear correlations were obtained between the fluorescence intensity 
(arbitrary units, a.u.) of the spots and the amount of the protein interro‑
gated in the arrays. Protein concentrations in the biopsies were calculated 
by interpolation in the respective linear plots.
Additional file 2: Table S1. Summary of diagnostic sensitivity of meta‑
bolic biomarkers in inflammatory myopathies. AUC, Area Under the Curve.
Additional file 3: Figure S2. Overexpression of PKM2 in DM. a Tissue 
extracts (30 µg) derived from two randomly selected muscle biopsies 
of control donors (CTR), polymyositis (PM), dermatomyositis (DM) and 
sporadic inclusion body myositis (IBM) and of the HCT116 cell line were 
fractionated on SDS‑PAGE and blotted against anti‑PKM2, anti‑GAPDH and 
anti‑LDH‑A. Electrophoretic migration of the protein is indicated to the left 
of each blot. b Histograms show the expression of the proteins (a.u.) when 
compared to the expression in HCT116 cells.
Additional file 4: Figure S3. Plasma levels of PKM2 by ELISA and RPPA. 
a Determination of PKM2 by ELISA in plasma samples of DM, sIBM and 
CRL patients. b Upper panel, scheme of printing of the plasma samples 
from CRL, sIBM, DM and PM patients. One nl of 1:20 diluted samples were 
spotted in quadruplicate. Black boxed: negative controls of BSA; Magenta 
boxed: standard curves of HCT116 cells; Brown boxed: positive controls of 
murine IgGs; Orange boxed: standard curve of PKM2 recombinant protein; 
Green boxed: samples from control donors (CTR); Blue boxed: samples 
from sIBM patients; Red boxed: samples from DM patients; Yellow boxed: 
sample from PM patients. Lower panel, parallel array processed with 
goat anti‑mouse IgGs CF647 as negative control. Please note the lack of 
cross‑reactivity against the human plasma IgGs. c The histogram shows 
the plasma levels of PKM2 quantified by RPPA assay. The results shown are 
mean ± S.E.M.
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